{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:39:15Z","timestamp":1794465555138,"version":"4.9.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,9]]},"abstract":"<jats:p>This study aimed to analyze the clinical characteristics of <jats:italic toggle=\"yes\">Gynura segetum<\/jats:italic> (Tusanqi)-induced hepatic sinusoidal obstruction syndrome (HSOS) and the benefits and risks of anticoagulant therapy for Tusanqi-induced HSOS. This was a retrospective analysis of 49 patients with Tusanqi-induced HSOS who were treated with anticoagulation or standard therapy between July 2006 and December 2022. Clinical manifestations included abdominal pain (n\u2005=\u200547) and peritoneal or pleural effusion (n\u2005=\u200546); 2 patients died. Nineteen patients requested standard medical treatment, while 30 were treated with anticoagulants. HSOS resolved within 6 months in 22 patients but did not resolve in 27 patients. The resolution rate was higher in the anticoagulant than standard treatment group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.037). Logistic regression analysis revealed that a history of chronic liver disease or treatment increased the risk of poor outcomes. Bleeding complications occurred in 6 patients in the anticoagulant treatment group. Early diagnosis and anticoagulant treatment are beneficial for rapid recovery after Tusanqi-induced HSOS. However, anticoagulant treatment is associated with the risk of multisite bleeding.<\/jats:p>","DOI":"10.1097\/md.0000000000035914","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:32Z","timestamp":1707509132000},"page":"e35914","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Anticoagulant therapy likely increases risk of bleeding in Gynura segetum-induced hepatic sinus obstruction syndrome"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-1407","authenticated-orcid":false,"given":"Youwen","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Daijiamen, Runzhou Distinct, Zhenjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Daijiamen, Runzhou Distinct, Zhenjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/1751-2980.12112","article-title":"Tusanqi and hepatic sinusoidal obstruction syndrome.","volume":"15","author":"Wang","year":"2014","journal-title":"J Dig Dis"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"e942","DOI":"10.1097\/MD.0000000000000942","article-title":"Tusanqi-related sinusoidal obstruction syndrome in china: a systematic review of the literatures.","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41401-020-00553-9","article-title":"Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China.","volume":"42","author":"Zhu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"R4-20250503","first-page":"2597","article-title":"Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) following hematopoietic stem cell transplant: insights and therapeutic advances.","volume":"38","author":"Nassereddine","year":"2018","journal-title":"Anticancer Res"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.3748\/wjg.v25.i28.3753","article-title":"Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.","volume":"25","author":"Yang","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/jgh.14612","article-title":"Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.","volume":"34","author":"Zhuge","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/MEG.0000000000001630","article-title":"Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study.","volume":"32","author":"Peng","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT).","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","article-title":"Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).","volume":"4","author":"Fan","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/hep.510290615","article-title":"Characterization of a reproducible rat model of hepatic veno-occlusive disease.","volume":"29","author":"DeLeve","year":"1999","journal-title":"Hepatology"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2010.07.031","article-title":"Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.","volume":"54","author":"Lin","year":"2011","journal-title":"J Hepatol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/toxins13100723","article-title":"Pyrrolizidine alkaloid-induced hepatotoxicity associated with the formation of reactive metabolite-derived pyrrole-protein adducts.","volume":"13","author":"Ma","year":"2021","journal-title":"Toxins (Basel)"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.2174\/1381612825666191007162024","article-title":"Gynura segetum related hepatic sinusoidal obstruction syndrome: a liver disease with high mortality and misdiagnosis rate.","volume":"25","author":"Ou","year":"2019","journal-title":"Curr Pharm Des"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1399-0012.2012.01604.x","article-title":"Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review.","volume":"26","author":"Zhang","year":"2012","journal-title":"Clin Transplant"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bmt.1705297","article-title":"Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis.","volume":"37","author":"Imran","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12876-018-0879-7","article-title":"Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study.","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:01:33Z","timestamp":1746316893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035914","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]}}}